
  
    
      
        Background_NNP
        Previously_RB limited_VBN to_TO case_NN series_NN ,_, [_NN 1_CD 2_CD 3_CD 4_CD ]_NN
        information_NN on_IN the_DT patient_NN characteristics_NNS and_CC course_NN of_IN
        human_JJ immunodeficiency_NN virus_NN or_CC acquired_VBN immunodeficiency_NN
        syndrome_NN associated_VBN nephropathy_NN (_( HIVAN_NNP )_) after_IN the_DT onset_NN of_IN
        end_NN stage_NN renal_JJ disease_NN (_( ESRD_NNP )_) has_VBZ been_VBN reported_VBN for_IN the_DT
        national_JJ population_NN of_IN US_NNP ESRD_NNP patients_NNS ._. [_NN 5_CD 6_CD ]_NN
        Substantial_NNP improvements_NNS in_IN the_DT survival_NN of_IN dialysis_NN
        patients_NNS with_IN HIV_NNP infection_NN have_VBP been_VBN noted_VBN after_IN 1995_CD ,_, [_NN 6_CD
        ]_NN and_CC have_VBP been_VBN attributed_VBN to_TO treatment_NN with_IN highly_RB active_JJ
        antiretroviral_NN therapy_NN (_( HAART_NNP )_) ._. [_NN 7_CD ]_NN Despite_IN these_DT
        encouraging_VBG reports_NNS ,_, the_DT morbidity_NN and_CC mortality_NN of_IN these_DT
        patients_NNS remains_VBZ high_JJ compared_VBN with_IN age-matched_JJ patients_NNS
        with_IN ESRD_NNP from_IN other_JJ causes_NNS ._. [_NN 6_CD ]_NN Despite_IN the_DT improving_VBG
        information_NN on_IN the_DT pharmacokinetics_NNS of_IN these_DT drugs_NNS in_IN
        dialysis_NN patients_NNS ,_, a_DT recent_JJ report_NN suggested_VBD that_IN only_RB 58_CD %_NN
        of_IN the_DT 62_CD HIV-infected_NNP patients_NNS with_IN ESRD_NNP were_VBD on_IN
        antiretroviral_NN therapy_NN ._. [_NN 8_CD ]_NN Use_NN of_IN angiotensin_NN converting_VBG
        enzyme_NN inhibitors_NNS (_( ACE_NNP )_) in_IN patients_NNS with_IN HIVAN_NNP is_VBZ
        associated_VBN with_IN delayed_VBN progression_NN to_TO ESRD_NNP ._. [_NN 9_CD 10_CD ]_NN Some_DT
        other_JJ reports_NNS have_VBP suggested_VBN that_DT use_NN of_IN ACE_NNP in_IN dialysis_NN
        patients_NNS may_MD improve_VB survival_NN ._. [_NN 11_CD ]_NN It_PRP is_VBZ possible_JJ the_DT
        use_NN of_IN ACE_NNP might_MD be_VB particularly_RB beneficial_JJ in_IN HIV_NNP infected_VBN
        patients_NNS with_IN ESRD_NNP particularly_RB those_DT with_IN HIV_NNP associated_VBN
        nephropathy_NN as_IN heavy_JJ proteinuria_NN often_RB continues_VBZ after_IN the_DT
        onset_NN of_IN dialysis_NN [_NN 12_CD ]_NN ._. Alternatively_RB ,_, risk_NN of_IN
        hyperkalemia_NN from_IN ACE_NNP in_IN patients_NNS with_IN HIVAN_NNP due_JJ to_TO
        associated_VBN tubulointerstitial_NN inflammation_NN and_CC renal_JJ
        tubular_JJ acidosis_NNS may_MD increase_VB mortality_NN ._. [_NN 13_CD ]_NN Although_IN a_DT
        recent_JJ single-center_JJ report_NN found_VBD no_DT benefit_NN of_IN ACE_NNP in_IN
        dialysis_NN patients_NNS with_IN HIVAN_NNP [_NN 14_CD ]_NN ,_, it_PRP is_VBZ not_RB clear_JJ
        whether_IN this_DT represents_VBZ national_JJ experience_NN ._.
        Recent_JJ anecdotal_JJ reports_NNS of_IN remission_NN of_IN HIVAN_NNP with_IN use_NN
        of_IN HAART_NNP are_VBP encouraging_VBG ._. However_RB ,_, the_DT prevalence_NN of_IN
        patients_NNS with_IN HIVAN_NNP who_WP develop_VBP ESRD_NNP may_MD not_RB decrease_VB ,_,
        because_IN of_IN improvement_NN in_IN survival_NN of_IN these_DT patients_NNS ,_,
        allowing_VBG them_PRP to_TO live_VB long_RB enough_RB to_TO reach_VB ESRD_NNP ._. [_NN 15_CD 16_CD 17_CD
        ]_NN Such_JJ patients_NNS may_MD even_RB be_VB more_RBR difficult_JJ to_TO manage_VB ,_, since_IN
        the_DT onset_NN of_IN HIVAN_NNP could_MD be_VB delayed_VBN until_IN these_DT patients_NNS
        develop_VBP resistance_NN to_TO the_DT therapy_NN ._. Therefore_RB ,_, HIVAN_NNP is_VBZ
        likely_JJ to_TO continue_VB as_IN a_DT major_JJ cause_NN of_IN ESRD_NNP in_IN young_JJ
        African-_NNP Americans_NNPS ._. Better_NNP understanding_NN of_IN factors_NNS
        associated_VBN with_IN poor_JJ outcomes_NNS in_IN patients_NNS with_IN HIVAN_NNP and_CC
        ESRD_NNP would_MD help_VB in_IN improving_VBG outcomes_NNS in_IN these_DT patients_NNS ._.
        More_RBR detailed_JJ information_NN on_IN the_DT metabolic_JJ ,_, cardiovascular_JJ
        and_CC chronic_JJ kidney_NN disease_NN specific_JJ characteristics_NNS of_IN
        HIVAN_NNP patients_NNS on_IN dialysis_NN ,_, as_RB well_RB as_IN the_DT use_NN and_CC possible_JJ
        benefit_NN of_IN certain_JJ medications_NNS ,_, especially_RB ACE_NNP and_CC
        antiretroviral_NN drugs_NNS in_IN this_DT population_NN ,_, would_MD supplement_VB
        previous_JJ reports_NNS ._. Further_RB ,_, use_NN of_IN a_DT national_JJ database_NN would_MD
        allow_VB the_DT comparison_NN of_IN HIVAN_NNP patients_NNS in_IN a_DT large_JJ at-risk_JJ
        population_NN and_CC allow_VB comparison_NN with_IN single_JJ center_NN studies_NNS
        that_WDT may_MD reflect_VB practices_NNS that_WDT may_MD not_RB be_VB representative_NN
        of_IN the_DT national_JJ as_IN a_DT whole_NN ._. Therefore_RB ,_, we_PRP analyzed_VBD data_NNS
        from_IN the_DT standard_JJ analysis_NN files_NNS of_IN the_DT 2000_CD United_NNP States_NNPS
        Renal_NNP Data_NNP System_NNP (_( USRDS_NNP )_) Dialysis_NNP Morbidity_NNP and_CC Mortality_NNP
        (_( DMMS_NNP )_) Wave_NNP 2_CD database_NN ._. The_DT primary_JJ objective_NN of_IN the_DT study_NN
        was_VBD to_TO examine_VB whether_IN patients_NNS with_IN HIVAN_NNP who_WP present_JJ to_TO
        chronic_JJ dialysis_NN had_VBD important_JJ differences_NNS in_IN clinical_JJ and_CC
        laboratory_NN parameters_NNS compared_VBN to_TO patients_NNS with_IN other_JJ
        causes_NNS of_IN ESRD_NNP and_CC to_TO assess_VB factors_NNS associated_VBN with_IN better_RB
        survival_NN such_JJ as_IN laboratory_NN parameters_NNS and_CC medication_NN
        use_NN ._.
      
      
        Methods_NNP
        
          Statistical_NNP analysis_NN
          Continuous_NNP variables_NNS are_VBP presented_VBN as_IN mean_NN ±_NN standard_JJ
          deviation_NN unless_IN otherwise_RB specified_VBN ._. Univariate_NNP analysis_NN
          was_VBD performed_VBN with_IN Chi-_NNP Square_NNP testing_NN for_IN categorical_JJ
          variables_NNS (_( Fisher_NNP exact_JJ test_NN used_VBN for_IN violations_NNS of_IN
          Cochran_NNP 's_POS assumptions_NNS ,_, meaning_VBG fewer_JJR than_IN 5_CD cases_NNS per_IN
          cell_NN )_) and_CC student_NN 's_POS t-test_JJ for_IN continuous_JJ variables_NNS (_( Mann_NNP
          Whitney_NNP test_NN or_CC logarithmic_JJ transformation_NN was_VBD used_VBN for_IN
          variables_NNS without_IN a_DT Gaussian_NNP distribution_NN ,_, verified_VBN by_IN
          visual_JJ inspection_NN and_CC goodness_NN of_IN fit_NN tests_NNS (_( Chi_NNP Square_NNP
          for_IN linear_JJ trend_NN )_) ._. Variables_NNP with_IN borderline_NN significance_NN
          (_( p_NN value_NN <_NN 0_CD ._. 1_CD in_IN univariate_NN analysis_NN )_) and_CC those_DT
          thought_VBD likely_JJ to_TO have_VB a_DT clinical_JJ relationship_NN with_IN HIVAN_NNP
          were_VBD entered_VBN into_IN the_DT multivariate_NN models_NNS ._. Stepwise_NNP
          (_( forward_RB step_NN likelihood_NN ratio_NN method_NN )_) Cox_NNP proportional_JJ
          hazards_NNS analysis_NN was_VBD used_VBN to_TO assess_VB the_DT association_NN
          between_IN baseline_NN factors_NNS and_CC HIVAN_NNP ,_, independent_JJ of_IN other_JJ
          factors_NNS ._. This_DT method_NN used_VBD the_DT most_RBS computationally_RB
          intensive_JJ method_NN for_IN calculating_VBG mean_NN hazard_NN ratios_NNS
          (_( approximations_NNS of_IN relative_JJ risk_NN )_) entering_VBG each_DT variable_NN
          into_IN the_DT model_NN and_CC removing_VBG those_DT that_WDT were_VBD no_DT longer_RB
          significant_JJ after_IN adjustment_NN for_IN all_DT other_JJ variables_NNS ._.
          Log-log_NNP plots_NNS were_VBD inspected_VBN to_TO verify_VB the_DT existence_NN of_IN
          proportional_JJ hazards_NNS ._. Estimated_VBN hazard_NN ratios_NNS (_( HR_NNP )_) along_IN
          with_IN corresponding_JJ 95_CD %_NN confidence_NN intervals_NNS (_( CI_NNP )_) and_CC p_NN
          values_NNS are_VBP reported_VBN for_IN all_DT regression_NN covariates_NNS ._. The_DT
          association_NN of_IN HIVAN_NNP with_IN mortality_NN was_VBD also_RB tested_VBN by_IN
          Cox_NNP regression_NN analysis_NN using_VBG adjusted_VBN hazard_NN ratios_NNS
          (_( AHR_NNP )_) ._. Hierarchically_NNP well-formed_JJ models_NNS were_VBD used_VBN in_IN the_DT
          assessment_NN of_IN interaction_NN terms_NNS ._. Collinearity_NNP diagnostics_NNS
          were_VBD evaluated_VBN both_DT from_IN the_DT output_NN of_IN the_DT statistical_JJ
          procedures_NNS and_CC by_IN manual_JJ generation_NN of_IN models_NNS including_VBG
          only_RB one_CD of_IN several_JJ variables_NNS with_IN close_JJ relationships_NNS
          (_( for_IN example_NN ,_, malnutrition_NN ,_, body_NN mass_NN index_NN and_CC serum_NN
          albumin_NN )_) ._. To_TO assess_VB for_IN possible_JJ confounding_VBG ,_, logistic_JJ
          regression_NN was_VBD also_RB performed_VBN to_TO assess_VB for_IN significant_JJ
          associations_NNS with_IN a_DT history_NN of_IN HIVAN_NNP using_VBG the_DT same_JJ
          covariates_NNS as_IN for_IN Cox_NNP Regression_NNP as_IN above_IN ._. Multiple_NNP
          methods_NNS were_VBD used_VBN to_TO assess_VB goodness_NN of_IN fit_NN with_IN all_DT
          variables_NNS ,_, including_VBG Nagelkerke_NNP r_LS 2_CD (_( an_DT attempt_NN to_TO
          quantify_VB the_DT proportion_NN of_IN explained_VBD "_'' variation_NN "_'' in_IN the_DT
          logistic_JJ regression_NN model_NN ,_, although_IN values_NNS for_IN r_LS 2_CD in_IN
          logistic_JJ regression_NN are_VBP much_RB lower_JJR than_IN for_IN linear_JJ
          regression_NN )_) and_CC the_DT c-statistic_JJ ,_, which_WDT is_VBZ the_DT receiver_NN
          operating_VBG curve_NN for_IN the_DT cumulative_JJ predicted_VBD probability_NN
          of_IN the_DT logistic_JJ regression_NN model_NN (_( 0_CD ._. 5_LS being_VBG equivalent_JJ to_TO
          chance_NN and_CC 1_CD ._. 0_CD equivalent_JJ to_TO 100_CD %_NN agreement_NN )_) ._.
        
      
      
        Results_NNS
        A_DT total_NN of_IN 4065_CD patients_NNS were_VBD included_VBN in_IN the_DT DMMS_NNP Wave_NNP
        2_CD cohort_NN ._. Of_IN these_DT ,_, 3621_CD patients_NNS had_VBD valid_JJ dates_NNS for_IN
        starting_VBG dialysis_NN in_IN 1996_CD ._. From_IN this_DT cohort_NN ,_, 3374_CD had_VBD
        sufficient_JJ information_NN to_TO calculate_VB follow-up_JJ times_NNS ._.
        Thirty-six_NNP of_IN these_DT patients_NNS had_VBD ESRD_NNP as_IN a_DT result_NN of_IN HIVAN_NNP ._.
        Mean_VB follow-up_JJ was_VBD 2_CD ._. 19_CD ±_NN 1_CD ._. 14_CD (_( standard_JJ deviation_NN )_) years_NNS ._.
        Characteristics_NNP of_IN all_PDT the_DT patients_NNS and_CC patients_NNS with_IN HIVAN_NNP
        are_VBP summarized_VBD in_IN Table_NNP 1_CD (_( see_VB Additional_JJ file_NN 1_LS )_) ._. As_IN
        shown_VBN ,_, in_IN this_DT file_NN factors_NNS positively_RB associated_VBN with_IN HIV_NNP
        in_IN univariate_NN analysis_NN included_VBD male_JJ gender_NN ,_, African_NNP
        American_JJ race_NN ,_, younger_JJR age_NN ,_, lower_JJR body_NN mass_NN index_NN ,_,
        decreased_VBD comorbidity_NN in_IN general_JJ ,_, increased_VBN rates_NNS of_IN
        malnutrition_NN and_CC smoking_VBG ,_, lower_JJR blood_NN pressure_NN and_CC
        cholesterol_NN ,_, higher_JJR serum_NN creatinine_NN ,_, lower_JJR serum_NN albumin_NN
        bicarbonate_NN ,_, and_CC decreased_VBD use_NN of_IN aspirin_NN and_CC calcium_NN
        channel_NN blockers_NNS ._. The_DT distribution_NN of_IN serum_NN PTH_NNP levels_NNS in_IN
        the_DT study_NN population_NN was_VBD severely_RB skewed_VBN ,_, with_IN a_DT skewness_NNS
        of_IN 2_CD ._. 49_CD and_CC a_DT kurtosis_NNS of_IN 9_CD ._. 08_CD ._. We_PRP elected_VBD to_TO use_VB
        non-parametric_JJ tests_NNS of_IN association_NN (_( the_DT Mann-_NNP Whitney_NNP test_NN )_)
        and_CC a_DT t-test_JJ of_IN logarithmically_RB transformed_VBN values_NNS of_IN PTH_NNP ._.
        Although_IN the_DT difference_NN in_IN serum_NN PTH_NNP levels_NNS between_IN
        patients_NNS with_IN HIVAN_NNP and_CC patients_NNS with_IN other_JJ causes_NNS of_IN renal_JJ
        disease_NN appeared_VBD large_JJ ,_, it_PRP was_VBD not_RB significant_JJ in_IN
        Mann-_NNP Whitney_NNP testing_NN (_( p_NN =_SYM 0_CD ._. 34_CD )_) or_CC t-tests_JJ of_IN
        logarithmically_RB transformed_VBN values_NNS of_IN serum_NN PTH_NNP (_( p_NN =_SYM
        0_CD ._. 64_CD )_) ._.
        Specific_JJ antiretroviral_NN agents_NNS are_VBP also_RB shown_VBN in_IN this_DT
        file_NN ._. The_DT most_RBS common_JJ agents_NNS used_VBN in_IN HIVAN_NNP patients_NNS were_VBD
        zidovudine_NN and_CC lamivudine_NN ._. Only_RB 22_CD (_( 61_CD %_NN )_) of_IN patients_NNS with_IN
        HIVAN_NNP received_VBD antiretroviral_NN agents_NNS ,_, and_CC only_RB nine_CD
        patients_NNS (_( 25_CD %_NN )_) received_VBD combination_NN antiretroviral_NN therapy_NN ._.
        Five_CD patients_NNS received_VBD both_DT zidovudine_NN and_CC lamivudine_NN (_( a_DT
        combination_NN later_RB called_VBD Combivir_NNP TM_NNP )_) ._. Other_JJ combinations_NNS
        included_VBD one_CD each_DT for_IN zidovudine-zalcitabine_JJ ,_,
        stavudine-saquinavir_JJ ,_, stavidine-lamivudine_JJ ,_, and_CC
        indinavir-lamivudine_JJ ._.
        Table_NNP 2_CD shows_VBZ factors_NNS independently_RB associated_VBN with_IN HIVAN_NNP
        in_IN logistic_JJ regression_NN ._. Factors_NNP included_VBD antiretroviral_NN
        therapy_NN ,_, male_JJ gender_NN ,_, African_NNP American_JJ race_NN ,_, younger_JJR age_NN ,_,
        lower_JJR serum_NN albumin_NN ,_, higher_JJR rates_NNS of_IN malnutrition_NN and_CC
        smoking_NN ,_, and_CC lower_JJR use_NN of_IN calcium_NN channel_NN blockers_NNS ._. There_EX
        were_VBD no_DT significant_JJ differences_NNS in_IN ACE_NNP use_NN by_IN either_DT HIV_NNP or_CC
        HIVAN_NNP status_NN ,_, either_CC unadjusted_JJ or_CC adjusted_VBN ._. There_EX was_VBD no_DT
        significant_JJ interaction_NN between_IN ACE_NNP and_CC antiretroviral_NN
        therapy_NN ._.
        Patients_NNS with_IN HIVAN_NNP had_VBD significantly_RB lower_JJR survival_NN
        compared_VBN to_TO patients_NNS with_IN other_JJ causes_NNS of_IN ESRD_NNP (_( Table_NNP 3_CD ,_,
        Figure_NN 1_LS )_) ._. Plots_NNP of_IN survival_NN by_IN ACE_NNP use_NN are_VBP shown_VBN for_IN HIVAN_NNP
        patients_NNS (_( Figure_NN 2_LS )_) and_CC for_IN the_DT entire_JJ study_NN cohort_NN (_( Figure_NN
        3_LS )_) ._. In_IN Cox_NNP Regression_NNP analysis_NN adjusted_VBN for_IN other_JJ factors_NNS
        known_VBN to_TO be_VB associated_VBN with_IN mortality_NN ,_, HIVAN_NNP was_VBD
        independently_RB associated_VBN with_IN increased_VBN risk_NN of_IN mortality_NN ,_,
        adjusted_VBN hazard_NN ratio_NN ,_, 4_CD ._. 74_CD ,_, 95_CD %_NN CI_NNP ,_, 3_CD ._. 12_CD -_: 7_CD ._. 32_CD ,_, p_NN <_NN
        0_CD ._. 0001_CD ._. ACE_NNP use_NN was_VBD not_RB significantly_RB associated_VBN with_IN
        mortality_NN in_IN the_DT entire_JJ cohort_NN in_IN Cox_NNP Regression_NNP ,_, and_CC it_PRP
        was_VBD not_RB significant_JJ as_IN an_DT interaction_NN term_NN with_IN HIVAN_NNP (_( p_NN =_SYM
        0_CD ._. 38_CD ,_, adjusted_VBN hazard_NN ratio_NN ,_, 1_CD ._. 64_CD ,_, 95_CD %_NN CI_NNP ,_, 0_CD ._. 55_CD -_: 4_CD ._. 87_CD )_) ._. In_IN
        stratified_JJ analysis_NN limited_VBN to_TO patients_NNS with_IN HIVAN_NNP ,_, ACE_NNP use_NN
        was_VBD not_RB significantly_RB associated_VBN with_IN mortality_NN (_( p_NN =_SYM 0_CD ._. 48_CD ,_,
        AHR_NNP =_SYM 1_CD ._. 88_CD ,_, 95_CD %_NN CI_NNP ,_, 0_CD ._. 33_CD -_: 10_CD ._. 83_CD )_) ._. Although_IN the_DT risk_NN of_IN death_NN
        of_IN patients_NNS with_IN HIVAN_NNP and_CC ESRD_NNP treated_VBD with_IN single_JJ
        antiretroviral_NN drug_NN was_VBD higher_JJR than_IN those_DT not_RB taking_VBG
        antiretroviral_NN agents_NNS ,_, patients_NNS on_IN multiple_JJ antiretroviral_NN
        drugs_NNS had_VBD a_DT lower_JJR hazard_NN ratio_NN in_IN adjusted_VBN analysis_NN (_( 0_CD ._. 62_CD ,_,
        95_CD %_NN CI_NNP ,_, 0_CD ._. 10_CD -_: 3_CD ._. 86_CD by_IN Cox_NNP Regression_NNP )_) ,_, however_RB this_DT was_VBD not_RB
        statistically_RB significant_JJ (_( Figure_NN 4_LS )_) ._. Among_IN patients_NNS with_IN
        HIVAN_NNP ,_, the_DT leading_VBG causes_NNS of_IN death_NN were_VBD AIDS_NNP (_( 50_CD %_NN )_) ,_,
        missing_VBG /_NN unknown_JJ (_( 10_CD ._. 7_CD %_NN )_) ,_, and_CC cardiac_JJ arrest_NN of_IN unknown_JJ
        cause_NN (_( 10_CD ._. 7_CD %_NN )_) ._. Factors_NNP independently_RB associated_VBN with_IN
        survival_NN in_IN HIVAN_NNP patients_NNS are_VBP shown_VBN in_IN Table_NNP 4_CD ._. The_DT only_JJ
        factor_NN independently_RB associate_JJ with_IN improved_VBN survival_NN was_VBD
        African_NNP American_JJ race_NN ,_, compared_VBN to_TO all_DT other_JJ races_NNS ._.
      
      
        Discussion_NNP
        The_DT present_JJ study_NN found_VBD that_IN only_RB 61_CD %_NN of_IN a_DT national_JJ
        sample_NN of_IN US_NNP dialysis_NN patients_NNS with_IN HIVAN_NNP received_VBD
        antiretroviral_NN therapy_NN ,_, consistent_JJ with_IN previous_JJ regional_JJ
        reports_NNS of_IN 58_CD %_NN use_NN of_IN anti-retroviral_JJ agents_NNS ,_, [_NN 8_CD ]_NN
        suggesting_VBG that_DT underutilization_NN of_IN antiretroviral_NN in_IN
        dialysis_NN patients_NNS with_IN HIVAN_NNP is_VBZ a_DT national_JJ problem_NN ._. HAART_NNP
        use_NN ,_, which_WDT the_DT present_JJ study_NN could_MD not_RB directly_RB measure_VB ,_, is_VBZ
        also_RB low_JJ in_IN dialysis_NN patients_NNS with_IN HIVAN_NNP ,_, at_IN 33_CD %_NN according_VBG
        to_TO a_DT recent_JJ single-center_JJ study_NN [_NN 14_CD ]_NN ._. We_PRP found_VBD no_DT
        beneficial_JJ effect_NN of_IN ACE_NNP on_IN survival_NN in_IN HIVAN_NNP ,_, also_RB
        consistent_JJ with_IN previous_JJ studies_NNS [_NN 14_CD ]_NN ._. The_DT survival_NN of_IN
        HIVAN_NNP patients_NNS on_IN dialysis_NN in_IN the_DT preset_JJ study_NN is_VBZ also_RB
        consistent_JJ with_IN previous_JJ reports_NNS [_NN 5_CD 6_CD ]_NN ._. One-year_NNP
        survival_NN of_IN patients_NNS with_IN HIVAN_NNP was_VBD only_RB 53_CD %_NN compared_VBN to_TO
        83_CD %_NN for_IN patients_NNS with_IN all_DT other_JJ causes_NNS of_IN ESRD_NNP ._. This_DT
        survival_NN is_VBZ lower_RBR than_IN reported_VBD recently_RB by_IN Ahuja_NNP et_CC al_NN ._. [_NN
        6_CD ]_NN in_IN HIV_NNP infected_JJ patients_NNS starting_VBG dialysis_NN in_IN the_DT
        United_NNP States_NNPS after_IN 1997_CD ,_, likely_JJ from_IN the_DT fact_NN that_IN
        patients_NNS included_VBN in_IN the_DT DMMS_NNP wave_NN 2_CD were_VBD recruited_VBN in_IN
        1996_CD ._. Although_IN data_NNS on_IN CD_NNP 4_CD counts_VBZ and_CC viral_JJ loads_NNS were_VBD
        unavailable_JJ from_IN the_DT database_NN (_( the_DT importance_NN of_IN which_WDT is_VBZ
        illustrated_VBN in_IN two_CD reviews_NNS ._. [_NN 19_CD 20_CD ]_NN HIVAN_NNP is_VBZ generally_RB a_DT
        late_JJ manifestation_NN of_IN HIV_NNP infection_NN ._. [_NN 21_CD ]_NN Therefore_RB ,_, use_NN
        of_IN antiretroviral_NN therapy_NN would_MD be_VB expected_VBN in_IN patients_NNS
        with_IN HIVAN_NNP in_IN the_DT absence_NN of_IN definite_JJ contraindications_NNS ,_,
        even_RB disregarding_VBG the_DT previously_RB cited_VBN reports_NNS of_IN a_DT
        possible_JJ beneficial_JJ effect_NN of_IN HAART_NNP on_IN the_DT course_NN of_IN HIVAN_NNP
        itself_PRP ._. However_RB ,_, in_IN the_DT present_JJ study_NN only_RB 61_CD %_NN of_IN patients_NNS
        with_IN HIVAN_NNP were_VBD receiving_VBG antiretroviral_NN therapy_NN and_CC 41_CD %_NN of_IN
        these_DT were_VBD only_RB on_IN single_JJ antiretroviral_NN therapy_NN ._. Although_IN
        not_RB statistically_RB significant_JJ ,_, there_EX was_VBD a_DT trend_NN towards_IN
        better_JJR survival_NN of_IN patients_NNS on_IN two_CD antiretroviral_NN drugs_NNS ._.
        None_NN of_IN the_DT patients_NNS was_VBD on_IN more_RBR then_RB two_CD antiretroviral_NN
        drugs_NNS ._. This_DT underutilization_NN of_IN antiretroviral_NN therapy_NN
        could_MD be_VB due_JJ hesitancy_NN on_IN the_DT part_NN of_IN the_DT infectious_JJ
        disease_NN specialists_NNS and_CC nephrologists_NNS for_IN using_VBG these_DT drugs_NNS
        due_JJ to_TO unavailability_NN of_IN data_NNS on_IN the_DT pharmacokinetics_NNS of_IN
        these_DT drugs_NNS in_IN patients_NNS on_IN dialysis_NN ._. Providers_NNP may_MD also_RB be_VB
        concerned_VBN about_IN the_DT nephrotoxicity_NN of_IN certain_JJ
        antiretroviral_NN agents_NNS ,_, notably_RB indinavir-associated_JJ crystal_NN
        induced_VBD renal_JJ failure_NN ,_, [_NN 22_CD ]_NN and_CC other_JJ antiretroviral_NN
        agents_NNS that_WDT require_VBP dose_NN adjustment_NN in_IN renal_JJ failure_NN ._. [_NN 22_CD
        ]_NN Urgent_NNP studies_NNS are_VBP therefore_RB needed_VBN to_TO understand_VB factors_NNS
        responsible_JJ for_IN this_DT underutilization_NN of_IN HAART_NNP in_IN these_DT
        patients_NNS ._. Similar_JJ underutilization_NN of_IN medications_NNS known_VBN to_TO
        be_VB beneficial_JJ in_IN patients_NNS with_IN chronic_JJ kidney_NN disease_NN has_VBZ
        also_RB been_VBN reported_VBN for_IN cardiovascular_JJ disease_NN ._. [_NN 18_CD 23_CD ]_NN ,_,
        suggesting_VBG such_JJ practice_NN may_MD not_RB be_VB an_DT isolated_VBN phenomenon_NN ._.
        However_RB ,_, the_DT long_JJ term_NN tolerability_NN and_CC efficacy_NN of_IN HAART_NNP
        has_VBZ not_RB been_VBN studied_VBN in_IN patients_NNS on_IN dialysis_NN ._.
        Although_IN a_DT benefit_NN of_IN ACE_NNP use_NN in_IN HIV_NNP infected_JJ patients_NNS
        has_VBZ been_VBN reported_VBN previously_RB ,_, [_NN 9_CD ]_NN the_DT benefits_NNS of_IN ACE_NNP in_IN
        retarding_VBG progression_NN of_IN renal_JJ failure_NN in_IN patients_NNS with_IN
        HIVAN_NNP did_VBD not_RB translate_VB into_IN improvement_NN of_IN survival_NN of_IN
        these_DT patients_NNS on_IN dialysis_NN ._. This_DT is_VBZ in_IN agreement_NN with_IN some_DT
        recommendations_NNS that_IN ACE_NNP use_NN ,_, to_TO be_VB effective_JJ ,_, must_MD start_VB
        early_RB in_IN the_DT course_NN of_IN HIVAN_NNP ._. As_IN the_DT number_NN of_IN patients_NNS
        with_IN HIVAN_NNP who_WP were_VBD treated_VBN with_IN ACE_NNP was_VBD small_JJ in_IN the_DT
        present_JJ cohort_NN ,_, further_JJ prospective_JJ studies_NNS are_VBP required_VBN to_TO
        validate_NN our_PRP$ initial_JJ observation_NN ._.
        In_IN comparison_NN to_TO patients_NNS with_IN other_JJ causes_NNS of_IN ESRD_NNP ,_, the_DT
        patients_NNS with_IN HIVAN_NNP included_VBN in_IN the_DT DMMS_NNP wave_NN 2_CD study_NN were_VBD
        younger_JJR ,_, the_DT majority_NN were_VBD African-_NNP Americans_NNPS and_CC had_VBD lower_JJR
        serum_NN albumin_NN and_CC more_RBR severe_JJ acidosis_NNS ._. Some_DT reports_NNS have_VBP
        suggested_VBN that_IN HIV_NNP can_MD infect_NN parathyroid_NN cells_NNS and_CC these_DT
        patients_NNS have_VBP low_JJ parathyroid_NN hormone_NN (_( PTH_NNP )_) and_CC 1_CD ,_, 25_CD
        dihydroxyvitamin_NN D_NNP 3_CD levels_NNS ._. [_NN 24_CD ]_NN However_RB ,_, this_DT did_VBD not_RB
        prevent_VB development_NN of_IN secondary_JJ hyperparathyroidism_NN in_IN
        patients_NNS with_IN HIVAN_NNP and_CC ESRD_NNP ._. The_DT mean_NN PTH_NNP level_NN of_IN the_DT
        patients_NNS with_IN HIVAN_NNP was_VBD 225_CD ±_NN 42_CD ._. 6_CD pcg_NN /_NN L_NNP ,_, although_IN lower_JJR
        was_VBD not_RB statistically_RB different_JJ from_IN patients_NNS with_IN causes_NNS
        of_IN ESRD_NNP ._.
        The_DT present_JJ study_NN has_VBZ several_JJ limitations_NNS :_: it_PRP is_VBZ
        observational_NN and_CC not_RB randomized_JJ ,_, therefore_RB ,_, confounding_VBG
        might_MD persist_VB despite_IN adjustment_NN ._. It_PRP is_VBZ a_DT random_JJ sample_NN of_IN
        all_DT hemodialysis_NNS patients_NNS ,_, not_RB the_DT total_JJ population_NN ,_,
        although_IN the_DT peritoneal_JJ dialysis_NN population_NN is_VBZ almost_RB fully_RB
        captured_VBN ._. Information_NN bias_NN could_MD have_VB arisen_VBN due_JJ to_TO
        mistakes_NNS in_IN coding_VBG ,_, especially_RB for_IN medications_NNS ._. We_PRP did_VBD not_RB
        know_VB the_DT duration_NN of_IN use_NN of_IN medications_NNS prior_RB to_TO the_DT study_NN
        start_NN ._. We_PRP were_VBD also_RB unable_JJ to_TO follow_VB changes_NNS in_IN variables_NNS
        over_IN time_NN ._. Therefore_RB ,_, we_PRP could_MD not_RB follow_VB changes_NNS in_IN blood_NN
        pressure_NN ,_, laboratory_NN values_NNS ,_, or_CC dialysis_NN adequacy_NN ._. This_DT
        most_RBS especially_RB applied_VBN to_TO possible_JJ changes_NNS in_IN medication_NN
        use_NN and_CC changes_NNS in_IN patient_NN dry_JJ weight_NN ._. These_DT same_JJ
        limitations_NNS apply_VBP to_TO other_JJ published_VBN studies_NNS using_VBG this_DT
        database_NN ._. In_IN addition_NN the_DT information_NN on_IN CD_NNP 4_CD count_NN and_CC
        plasma_NN viral_JJ load_NN in_IN patients_NNS with_IN HIVAN_NNP was_VBD not_RB available_JJ
        and_CC this_DT could_MD be_VB an_DT important_JJ uncorrected_JJ confounding_VBG
        factor_NN ._. We_PRP could_MD not_RB assess_VB factors_NNS associated_VBN with_IN HIV_NNP
        seropositivity_NN or_CC AIDS_NNP due_JJ to_TO the_DT high_JJ percentage_NN of_IN
        patients_NNS with_IN missing_VBG values_NNS for_IN these_DT variables_NNS ._.
        In_IN summary_NN ,_, we_PRP conclude_VBP that_IN patients_NNS with_IN HIVAN_NNP have_VBP a_DT
        lower_JJR survival_NN compared_VBN to_TO patients_NNS with_IN ESRD_NNP from_IN other_JJ
        causes_NNS ._. Antiretroviral_NNP therapy_NN is_VBZ underutilized_VBN and_CC the_DT use_NN
        of_IN ACE_NNP does_VBZ not_RB improve_VB survival_NN of_IN these_DT patients_NNS ._. Future_NNP
        prospective_JJ studies_NNS are_VBP required_VBN to_TO determine_VB efficacy_NN and_CC
        tolerability_NN of_IN HAART_NNP and_CC ACE_NNP inhibitors_NNS in_IN patients_NNS with_IN
        HIVAN_NNP and_CC ESRD_NNP ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' contributions_NNS
        KCA_NNP performed_VBD the_DT primary_JJ data_NN analysis_NN and_CC collaborated_VBD
        in_IN the_DT writing_NN of_IN the_DT manuscript_NN ._.
        FCT_NNP derived_VBD the_DT algorithms_NNS for_IN the_DT medication_NN variables_NNS
        and_CC collaborated_VBD in_IN the_DT writing_NN of_IN the_DT manuscript_NN ._.
        LYA_NNP provided_VBD the_DT USRDS_NNP CD_NNP data_NNS files_NNS and_CC supervised_VBD the_DT
        project_NN ,_, and_CC collaborated_VBD in_IN the_DT writing_NN of_IN the_DT
        manuscript_NN ._.
        TSA_NNP collaborated_VBD in_IN the_DT writing_NN of_IN the_DT manuscript_NN ._.
      
      
        Note_VB
        The_DT opinions_NNS are_VBP solely_RB those_DT of_IN the_DT authors_NNS and_CC do_VBP not_RB
        represent_VB an_DT endorsement_NN by_IN the_DT Department_NNP of_IN Defense_NNP or_CC
        the_DT National_NNP Institutes_NNPS of_IN Health_NNP ._. This_DT is_VBZ a_DT U_NNP ._. S_NNP ._.
        Government_NN work_NN ._. There_EX are_VBP no_DT restrictions_NNS on_IN its_PRP$ use_NN
      
    
  
